Researchers at UEA have said CADD522 works against all the main types of primary bone cancer.
The team behind the research have said: “it could be the most important drug discovery in the field for more than 45 years”.
Image: google pexels
Bone cancer is primarily found in children, and the CADD522 drug is set to improve survival rates. It also means patients are less likely to need surgery that can cause disabilities as they can rely on the drug instead
Human trials have yet to begin but after discovering the survival rate of mice with bone cancer went from 42% to 50%, UEA researchers are awaiting confirmation to begin human trials.